大脑脊髓中高的DOPA脱碳酶水平预测了帕金森病的认知衰退
Andrea Sturchio1,2, Wojciech Paslawski1, Shervin Khosousi1
1Department of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institutet, Stockholm, Sweden.
Movement disorders clinical practice
|September 24, 2025
概括
大脑脊髓液DOPA脱碳酶 (DDC) 预测了帕金森病 (PD) 的认知衰退. 这种新兴的生物标志物在多个队列中显示出与PD患者未来认知障碍的显著关联.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 神经退行性疾病 神经退行性疾病
背景情况:
- 脑脊液 (CSF) 中的DOPA脱碳酶 (DDC) 是帕金森病 (PD) 的新兴生物标志物.
- 脊髓中DC水平与非运动性症状 (尤其是认知衰退) 之间的关系尚不清楚.
研究的目的:
- 为了研究基线CSF DDC水平与帕金森病患者未来认知衰退之间的关联.
- 确定CSF DDC是否可以作为PD认知障碍的预测生物标志物.
主要方法:
- 用近距离延伸试验测量了CSF DDC水平.
- 分析了来自三个队列 (生物公园,PPMI,PDBP) 的纵向数据.
- 基线CSF DDC与蒙特利尔认知评估 (MoCA) 评分随着时间的推移而相关.
主要成果:
- 在生物公园队列中,CSF DDC与认知能力下降有显著的关联 (P < 0.0001).
- 在PDBP/PPMI队列中也发现了显著的关联 (P < 0.0001).
- 这些关联在调整为勒沃多巴相当的每日剂量和新发病患者后仍然显著.
结论:
- 脑脊髓DDC是帕金森病认知衰退的潜在预测生物标志物.
- 这一发现支持CSF DDC在识别患有认知障碍风险的PD患者中的实用性.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.2K
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.3K
相关概念视频
Parkinson's Disease: Treatment
986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia
523
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
523
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
